Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone
June 11 2023 - 8:05AM
MannKind Corporation (Nasdaq: MNKD) will host
Connecticut Governor Ned Lamont for a tour of its headquarters on
Monday, June 12. The visit coincides with MannKind reaching a
manufacturing milestone as it has successfully scaled-up operations
for increased production capacity of Tyvaso DPI®.
Through MannKind’s partnership with United Therapeutics the
current expansion project represents a $60 million investment.
Construction is ongoing to build out new manufacturing space
designed to expand production in anticipation of the continued
growth of Tyvaso DPI. In the past two years, MannKind has
experienced more than a 250% increase in its Connecticut workforce
across manufacturing, R&D and support functions.
DATE/TIMES: |
MONDAY, JUNE 12, 2023 |
|
10:00 a.m. – 11:00 a.m. |
|
|
LOCATION: |
MannKind |
|
40 Taylor Street (Danbury,
CT) |
|
|
VISUALS/SOUND: |
- Governor Lamont tours facility
with MannKind CEO Dr. Michael Castagna and COO Lauren Sabella |
|
- Construction underway on
“clean rooms” and spray dry equipment in new manufacturing
space |
|
- Demonstration of
MannKind’s innovative Technosphere® particle and device
technologies |
|
- Production personnel
producing the particle technology used as part of our inhaled
insulin (Afrezza®) as well as Tyvaso DPI |
|
|
MANNKIND: |
MannKind Corporation focuses on
the development and commercialization of innovative therapeutic
products and devices to address serious unmet medical needs for
those living with endocrine and orphan lung diseases. We are
committed to using our formulation capabilities and device
engineering prowess to lessen the burden of diseases such as
diabetes, pulmonary arterial hypertension (PAH) and nontuberculous
mycobacterial (NTM) lung disease. Our signature technologies –
dry-powder formulations and inhalation devices – offer rapid and
convenient delivery of medicines to the deep lung where they can
exert an effect locally or enter the systemic circulation. |
CONTACT: |
MannKind Corporate Communications |
|
Christie Iacangelo (on-site) |
|
(818) 292-3500 (mobile) |
|
ciacangelo@mnkd.com |
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2024 to May 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From May 2023 to May 2024